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BACKGROUND: The X-linked inhibitor of apoptosis protein (XIAP), an endogenous apoptosis suppressor, can determine the level of
caspase accumulation and the resultant response to apoptosis-inducing agents such as cisplatin in epithelial ovarian cancer (EOC).
In addition, the mismatch repair protein, hMLH1, has been linked to DNA damage-induced apoptosis by cisplatin by both
p53-dependent and -independent mechanisms.
METHODS: In this study, hMLH1 expression was correlated with clinical response to platinum drugs and survival in advanced stage
(III–IV) EOC patients. We then investigated whether MLH1 loss was a determinant in anti-apoptosis response to cisplatin mediated
by XIAP in isogenic and established EOC cell lines with differential p53 status.
RESULTS: The percentage of cells undergoing cisplatin-induced cell killing was higher in MLH1-proficient cells than in MLH1-defective
cells. In addition, the presence of wild-type hMLH1 or hMLH1 re-expression significantly increased sensitivity to 6-thioguanine, a
MMR-dependent agent. Cell-death response to 6-thioguanine and cisplatin was associated with significant proteolysis of MLH1, with
XIAP destabilisation and increased caspase-3 activity. The siRNA-mediated inhibition of XIAP increased MLH1 proteolysis and cell
death in MLH1-proficient cells but not in MLH1-defective cells.
CONCLUSION: These data suggest that XIAP inhibitors may prove to be an effective means of sensitising EOC to MLH1-dependent
apoptosis.
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A yet unmet need exists for novel therapeutic strategies to
overcome resistance to chemotherapeutic treatment in epithelial
ovarian cancer (EOC) with functionally inactivated p53. This
subtype characterises 40–70% of ovarian cancers and renders
a chemoresistant phenotype that is more difficult to overcome
than that in p53 wild-type (wt) tumours (Lavarino et al, 2000;
Canevari et al, 2006). Although p53 status has a leading function
in determining the efficacy of apoptotic signalling, tumour cells
including EOC can evade apoptosis using multiple mechanisms
(Johnstone et al, 2002; Kaufmann and Vaux, 2003; Quintieri et al,
2007). The inhibitor of apoptosis protein (IAP) family has a
significant function in apoptosis resistance because of the unique
ability of most of the family members (IAP1, IAP2, Livin and
XIAP) to inhibit both initiator- and effector caspases (Liston et al,
1996; Ambrosini et al, 1997). The X-linked inhibitor of apoptosis
protein (XIAP) is considered to be one of the most potent IAPs and
a versatile caspase inhibitor (Deveraux et al, 1997; Devi, 2004).
Multiple studies in EOC (Sasaki et al, 2000; Asselin et al, 2001;
Li et al, 2001; Mansouri et al, 2003; Yang et al, 2005) and other
cancers (Amantana et al, 2004; Schimmer et al, 2006;
Aird et al, 2008) have identified XIAP suppression to be a key
mechanism in chemotherapy resistance. The acquisition of
cisplatin resistance is associated with the ability of treated cells
to upregulate XIAP expression. In addition, XIAP downregulation
can induce apoptosis in chemoresistant EOC cells, although
apparently only in cells that have a functionally active p53.
However, cancer cells with mutant p53 can undergo apoptosis in
response to cisplatin by p53-independent mechanisms; indeed, in
some EOC cell lines, the activity of caspase-3 is more predictive of
apoptotic response than is the p53 status (Gong et al, 1999;
Kolfschoten et al, 2002). Recently, hMLH1, a key DNA mismatch
repair (MMR) protein, has been identified as a substrate of
caspase-3-mediated proteolysis, resulting in the generation of a
pro-apoptotic carboxyl-terminal product (Chen et al, 2004). The
MLH1 is one of five proteins crucial to MMR function, the loss of
which is associated with the acquisition of a mutator phenotype,
including microsatellite instability (MSI) and predisposition to
cancer (Jiricny, 2006). The MMR pathway reduces spontaneous
mutation through the recognition and repair of DNA base–base
mismatches and insertion–deletion loops generated during
replication (Bellacosa, 2001; Kunkel and Erie, 2005; Iyer et al,
2006). In addition, MMR status is associated with cytotoxic cellular
responses to various chemotherapeutics (Fink et al, 1998a,b)
because of the MMR-dependent activation of cell-cycle checkpoint Revised 20 May 2009; accepted 11 June 2009
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ship between MMR status and sensitivity to cisplatin and platinum
analogues has been widely reported (Aebi et al, 1996; Drummond
et al, 1996; Brown et al, 1997; Fink et al, 1998b; Moreland et al,
1999; Massey et al, 2003; Helleman et al, 2006). Earlier studies
using repair-defective variants of the A2780 (MLH1 proficient, wt-
p53) ovarian cell line have shown that MLH1 restoration sensitises
cells to DNA-damaging agents, although sensitivity to cisplatin
remained significantly dependent on p53 function (Aquilina et al,
2000; Branch et al, 2000). Consistent with this, cisplatin-resistant
ovarian cell lines have been observed to acquire an MSI phenotype
and are defective in strand-specific MMR (Watanabe et al, 2001).
Several reports link MLH1 status and clinical response (CR) in
cancer patients (O’Brien and Brown, 2006). In contrast, some
clinical reports (Scartozzi et al, 2003; Helleman et al, 2006) suggest
no direct association between cisplatin response and MMR status
in primary ovarian cancers.
In this study, MLH1 expression levels correlated with CR and
increased survival among advanced stage EOC patients. Unselected
ovarian cell lines, OVCAR3, which has wt MLH1 and MLH1-
defective SKOV3, were compared with the A2780-MMR-defective
variant, A2780-MNU1, in which hMHL1 was re-expressed by stable
transfection (Aquilina et al, 2000). MLH1 proteolysis and XIAP
destabilisation were observed in cisplatin response and 6-thiogua-
nine (6-TG)-mediated apoptosis. In addition, MLH1 proteolysis
increased active forms of caspase-3 and -9, and decreased cell
viability was observed when XIAP was specifically inhibited using a
siRNA in the MLH1-proficient and not in the MLH1-deficient
ovarian cancer cells. Our study identifies a potential inverse
correlation between MLH1 expression and XIAP anti-apoptotic
activity in chemotherapy response in ovarian cancer cells.
MATERIALS AND METHODS
Cell culture and viability assay
The EOC cell lines were cultured in accordance with the
manufacturer’s recommended media (American Type Culture
Collection, Manassas, VA, USA). A2780MNU1-MLH1 and
A2780MNU1 cell lines were cultured according to earlier studies
(Aquilina et al, 2000; Mohd et al, 2006). Cells at 50% confluence in
a 96-well plate (Corning Incorporated, Corning, NY, USA) were
treated with 0–200mmoll
 1 cisplatin (Sigma Chemical Co.,
St Louis, MO, USA) for 24h in a serum-containing medium.
Cell were then incubated at 371C for 2h in a medium contain-
ing 0.5gl
 1 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT; Sigma Chemical Co.), and a proliferation assay
was conducted as reported earlier (Amantana et al, 2004; Aird
et al, 2008). In some experiments, cell viability was also deter-
mined by Trypan blue exclusion assay (Aird et al, 2008).
Clonogenecity assay
Clonogenic survival of individual cultures after exposure to 6-TG
was performed as described (Buermeyer et al, 1999). Cells were
exposed to the indicated concentrations (0–10mM) of 6-TG diluted
into growth media for 7–10 days, and surviving colonies (greater
than 100 cells) were counted. The results for each dose are
reported as the percentage of surviving colonies relative to mock-
treated cultures, and represent the average (þ/  standard
deviations) of a minimum of 3–4 experiments.
Western immunoblots
Cells were harvested and immediately lysed in an NP40 cell lysis
buffer (Biosource, Carlsbad, CA, USA), subjected to SDS–PAGE
under reducing conditions and transferred as reported earlier
(Aird et al, 2008). The membranes were probed overnight with a
primary antibody against XIAP (1:1000 dilution; BD Transduction
Laboratories, Lexington, KY, USA), PKC-d (1:1000; Cell
Signaling Technology, Beverly, MA, USA), procaspase-9 (1:1000,
Neomarker, Fremont, CA, USA), MLH1, PMS2 and MSH6 (1:500,
BD Pharmingen, Lexington, KY, USA) at 41C. Immunoreactive
bands were visualised as reported earlier (Aird et al, 2008). b-Actin
or GAPDH served as loading control by re-probing the same
membrane with an antibody (1:4000; Calbiochem, La Jolla, CA,
USA) or probed after first stripping the membrane in a stripping
buffer (100mmoll
 1 2-mercaptoethanol-2% SDS-62.5mmoll
 1
Tris-HCl (pH 6.7)) at 501C for 30min, followed by a washing
and blocking procedure as described above.
siRNA delivery
A total of 100nM XIAP siRNA, GAPDH control siRNA (Cell
Signaling) or control siRNA (50-VUUCUCCGAACGUGUCACGU-30,
random sequence (Qiagen, Valencia, CA, USA) was transfected into
cells as per manufacturer’s instructions and earlier study (Aird et al,
2008) and incubated at 371C for 48h.
Active caspase-3 detection
A PE-conjugated polyclonal active caspase-3 Ab apoptosis kit (BD
Pharmingen) was used to quantify apoptosis by detecting the levels
of active caspase-3, according to the manufacturer’s directions.
Cells were treated with vehicle, cisplatin (24h) or with various
siRNA (48h). The cells were harvested and washed twice with
cold PBS, then resuspended in Cytofix/Cytoperm solution at a
concentration of 1 10
6 cells per 0.5ml and incubated for
20min on ice. The cells were pelleted, washed, resuspended in
0.5ml Perm/Wash Buffer and analysed with a FACScalibur flow
cytometer (Becton Dickenson, San Jose, CA, USA).
MLH1 expression analysis in ovarian cancer patients
Affymetrix U133A gene expression microarray data (Santa Clara,
CA, USA) from which hMLH1 expression levels were obtained
have been described earlier (Berchuck et al, 2005). For this study,
54 of these patients with stage III or IV serous EOC, who received
platinum-based chemotherapy, were included. Patients in this data
set lived for o3 years (N¼30) or for longer than 7 years (N¼24)
after diagnosis. Log-transformed gene expression values were
calculated using robust multiarray analysis (Irizarry et al, 2003).
The probe for hMLH1 (202520_s_at) on the Affymetrix U133A
genechip was used for analysis. Two-tailed, unpaired t-tests were
used to compare the expression of hMLH1 in patients on the basis
of CR and survival.
Statistical analysis
Statistical analyses were performed using GraphPad Prism 4.0
(La Jolla, CA, USA). Differences were considered significant at
Po0.05. Data are expressed as mean±s.e.m.
RESULTS
Elevated MLH1 correlates with ovarian cancer patient
survival
To correlate MLH1 expression with clinical outcome in patients
with ovarian cancer, microarray expression data (as described in
Materials and Methods section) were analysed for a total of 54
patients with advanced stage serous EOC, who had received either
cisplatin or carboplatin as part of their primary chemotherapeutic
treatment. Patients exhibiting a complete clinical response (CCR)
(CA125 o20Uml
 1; CAT scan and office exam showing no
evidence of disease, assessed 1 month after the patient’s last cycle
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sof chemotherapy) had higher levels of MLH1 compared with
patients with an incomplete clinical response (ICR) (P¼0.01, 95%
confidence interval, 0.057–0.45), as shown in Figure 1A, top panel.
Patients with higher levels of MLH1 also exhibited a survival
advantage, with elevated levels of MLH1 mRNA present in tumours
from women who lived longer than 7 years after diagnosis,
compared with women who lived for o3 years after diagnosis
(P¼0.0005, 95% confidence interval, 0.15–0.52), as shown in
Figure 1A, bottom panel. Thus, the MLH1 status in this patient
cohort was associated both with increased CR and with increased
long-term patient survival. Although the results of our analysis of
MLH1 in EOC patients were consistent with earlier reports
associating MLH1 status with CR in ovarian cancer patients, it is
clear that MLH1 is not the sole determinant, and that other factors
must also influence patient response and survival, in particular
apoptotic dysregulation.
MLH1 expression and response to cisplatin and 6-TG
As published preclinical and clinical studies show that p53 status
may not by itself predict cellular response to cisplatin, we
investigated the apoptotic pathway engaged in response to MLH1-
dependent signalling in a set of MLH1-proficient and MLH1-
deficient EOC cells with an inactive or null p53 status. Two widely
studied ovarian tumour cell lines – OVCAR3 (expressing wt
hMLH1) and SKVO3 (deficient in endogenous MLH1) – were
characterised along with A2780MNU1, an MLH1 and a p53-
deficient clonal derivative of A2780. The parental A2780 is a well-
characterised ovarian carcinoma cell line that is proficient in MMR
and has an intact p53 response. Human MLH1 was re-expressed in
A2780MNU1 by transfection to create a clonal cell derivative –
A2780-MNUI-MLH1 – and the corresponding vector-only-trans-
fected A2780-MNU1 vector lines. An immunoblot analysis of the
MMR status (MLH1, PMS2, MSH6, key members of MMR family)
(Figure 1B) reveals an MSH6 protein expression in all four
cell lines irrespective of MLH1 status. The MLH1 as well as the
PMS2 protein were expressed and accumulated in MLH1-positive
cell lines (A2780MNU1-MLH1, OVCAR3 and OVCAR5), whereas
no MLH1 and decreased PMS2 levels were detected in A2780MNU1
cells and SKOV3 cells, consistent with the role of MLH1 in
stabilising PMS2.
A2780MNU1-MLH1, A2780-MNU1 vector, OVCAR3 and SKVO3
cells were evaluated for sensitivity to 6-TG, a chemotherapeutic
purine nucleoside analogue, the primary mechanism of action
of which is dependent on the presence of a functional DNA
MMR system. The hMLH1 re-expression in A2780MNU1 cells
MSH6
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Figure 1 MLH1 expression and chemotherapy sensitivity in ovarian cancer cells and patients. (A) Correlation of MLH1 mRNA expression in microarray
analysis using log-transformed Robust Multiarray Analysis values (y axis) from 54 stage III or IV ovarian cancer patients with clinical response (top graph) and
survival (bottom graph) as described in the text. CCR refers to complete clinical response and ICR refers to incomplete clinical response. (B) The cellular
abundance of MLH1, MSH6 and PMS2 was determined by immunoblot analysis of whole-cell lysates prepared from MLH1-deficient (SKVO3 and
A2780MNU1 vector, a cisplatin-resistant variant of the A2780 ovarian carcinoma cell line) and hMLH1-proficient (OVCAR3, OVCAR5 and A2780MNU1-
MLH1) cells. The membranes were stripped and reprobed with b-actin antibody to ensure an equal protein loading. Arrows indicate 84kDa MLH1, 96kDa
PMS2, 160kDa MSH6 and 35kDa b-actin bands. (C) 6-thioguanine clonogenic assay. Top graph. A2780-MNU1-MLH1 compared with the MLH1-defective
A2780-MNU1vector. Bottom graph. OVCAR3, which has wild-type MLH1 compared with MLH1-defective SKOV3 cells. Cells were treated with varying
amounts of 6-TG for 24h and exposed to a drug-free medium for 8 days. Cell viability in C and D was determined by clonogenicity analysis. Values are
mean±s.e.m. (n¼3). (D) Cisplatin MTT proliferation assay. Cells as indicated in top and bottom graphs were treated with different concentrations of
cisplatin for 24h, with proliferation determined by MTT assay. Bars represent mean±s.e.m. (n¼3, each experiment in triplicate).
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ssignificantly increased sensitivity to 6-TG compared with that
in the MLH1-deficient A2780MNU1 vector, viability being
determined by clonogenic survival (Figure 1C). The appearance
of apoptotic cells was delayed and followed a G2/M phase of
cell-cycle arrest (data not shown). Similarly, OVCAR3 cells, which
have endogenous hMLH1, were highly sensitive to 6-TG compared
with hMLH1-defective SKOV3, (Figure 1D), revealing that 6-TG
response was dependent on MLH1 expression and was potentially
p53 independent, as all the above four cell lines have non-
functional p53.
The effect of wt MLH1 or MLH1 restoration on cisplatin
sensitivity was characterised by treating the four cell lines with
cisplatin using published dose ranges 0–200mM; MTT assay was
used to determine growth and cell proliferation at 24h. Data in
Figure 1D identify OVCAR3 to be the most sensitive to cisplatin
treatment, followed by A2780-MNU1-MLH1, the A2780-MNU1
vector and SKVO3. Rounding of cells as observed by micro-
scopy (data not shown) and the measurement of the percentage
of cells undergoing cisplatin-mediated cell death by Trypan
blue cell exclusion assay at 24h and 48h showed decreased cell
viability at a lower cisplatin concentration or at an earlier
time point in hMLH1-proficient cells compared with that in
hMLH1-defective counterparts (50% viability compared with
control at 50mM in A2780MNU1-MLH1 vs 200mM in the
A2780MNU1 vector, and 10mM in OVCAR3 at 48h vs 100mM in
SKOV3 at 48h).
Overall, MLH1 was critical for 6-TG response, and a trend
towards decreased cell viability in response to cisplatin was
observed in MLH1-proficient cells.
Destabilisation of XIAP and PKC-d cleavage in cisplatin
and 6-TG-responsive MLH1-proficient ovarian cancer cells
As cisplatin caused decreased cell viability in the MLH1-proficient
cells tested, the expression of apoptotic- and anti-apoptotic
proteins was conducted in attached and detached cisplatin-treated
cell lysates at doses that showed significant detached cells and
decreased cell viability at 24h (50 and 200mM) for A2780MNU1-
MLH1 and OVCAR3. This was compared with doses and time
points on the basis of a 50% decrease in viability for MLH1-
deficient cell lysates (200mM in the A2780MNU1 vector at 24h and
100mM in SKOV3 at 48h).
Immunoblot analysis (Figure 2A) of the expression of XIAP
revealed a marked XIAP cleavage starting to occur in the detached
cell population at 50mM and in both attached and detached cell
populations at 200mM in cisplatin-treated A2780MNU1-MLH1 cells
and OVCAR3. In contrast, XIAP cleavage was only observed in the
detached 200mM concentration of cell lysates of the A2780-MNU1
vector at 24h and at 200mM in SKOV3 at 48h. Further, decrease/
proteolysis of XIAP corresponded with a decrease in inactive
procaspase-9, consistent with the ability of intact XIAP to suppress
apoptosis by binding procaspase-9 and not allowing enzymatic
cleavage to its active form. Apoptotic cell populations were also
quantified using antibodies to active caspase-3-PE at 24h by flow
cytometry, which revealed an increase in the number of cells
positive for the active caspase-3 protein in the A2780MNU1-MLH1
(Figure 2B, top graph) and OVCAR3 (Figure 2B, bottom graph)
cells treated with cisplatin compared with that in the MLH-1-
deficient cell lines in each graph panel.
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Figure 2 Analysis of XIAP expression in lysates from cisplatin-treated ovarian cells. (A) Immunoblot analysis of XIAP (55kDa intact and 30kDa
proteolytic fragment) and procaspase-9 indicated. Top panel: comparison of MLH1-proficient A2780MNU1-MLH1 and MLH1-deficient A2780MNU1
vector; bottom panel: comparison of OVCAR3 (MLH1 positive) and SKVO3 (MLH1 deficient) ovarian cancer cells. A indicates adherent and D indicates
detached in the immunoblots. (B) Graphical representation of relative cell numbers expressing active caspase-3 analysed by flow cytometric analysis using
anti-caspase-3-PE antibody in the indicated cell lines treated with cisplatin at 24h.
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sSimilar to cisplatin response, XIAP proteolysis (Figure 3)
corresponded with sensitivity to 6-TG (the earlier Figure 1 shows
less than 50% cell survival starting at 3mM 6-TG dose) in MLH1-
proficient A2780MNU1-MLH1 and OVCAR3 cells. In MLH1-
proficient cells (Figure 3A, left panel and 3B), the 30kDa
proteolysed fragment of XIAP started appearing in the detached
cells after 2 days of treatment with 3mM 6-TG concentration, which
increased with dose and time. In contrast, the appearance of the
XIAP cleavage product was observed 3–4 days after treatment with
a higher 6-TG (6mM) concentration in MLH1-deficient cells
(Figure 3A, right panel; Figure 3C).
Furthermore, in MLH1-proficient cells, proteolysis of PKC-d
(Figure 4), a caspase-3 substrate and marker of apoptotic cell
death, was identified in the lysates of detached cell populations at
both 3 and 6mM 6-TG treatment concentrations on days 2, 3 and 4
in MLH1-proficient cells compared with a 6mM 6-TG concentration
in MLH1-deficient cell lysates (Figure 4A). Similarly, the 40kDa
PKC-d proteolytic fragment was observed in cell lysates of
cisplatin-treated A7280-MNU1-MLH1-detached cells (50 and
200mM) compared with the appearance of the 40kDa fragment at
200mM detached cells in A2780-MNU1 vector cells (Figure 4A).
b-Actin is shown with each blot as a loading control.
The combined results show that MLH1-proficient cells are
more sensitive to a cisplatin-mediated decrease in cell viability,
corresponding to a significant destabilisation of XIAP, increased
caspase-3 and -9 and PKC-d proteolysis.
MLH1 cleavage in cisplatin and 6-TG-induced apoptosis in
ovarian cancer cells
To determine the effect of apoptosis signalling on MLH1 expres-
sion, MLH1 immunoblot analyses were conducted for lysates of
A2780-MNU1-MLH1 and OVCAR3 cells treated with 6-TG
(Figure 5A) and cisplatin (Figure 5B). Data show a decrease in
MLH1 expression in a dose- and time-dependent manner after
6-TG and cisplatin treatment in the detached cell lysates of the
two MLH1-proficient cell lines. Further, a significant proteolysis of
84kDa intact MLH1 to approximately 44kDa fragment was also
observed in A2780-MNU1-MLH1 in a dose- and time-dependent
manner (Figure 5A and B, top panels). The MLH1 cleavage
fragment was evident in cells that had started detaching than in
adherent cells. The GAPDH or b-actin are shown as loading
controls. The extent to which this fragment contributes to the
MLH1-dependent signalling of apoptosis is currently under
investigation.
XIAP inhibition selectively decreases cell viability in
MLH1-proficient ovarian cancer cells by MLH1 proteolysis
Cisplatin sensitivity in ovarian cancer has been correlated with
inhibition of XIAP, consistent with the observations in this study
(Figure 2). In addition, XIAP destabilization in cisplatin- and 6-
TG-sensitive MLH1-proficient cells corresponded with MLH1
decrease and/or increased proteolysis. (Figure 5). To understand
the relationship between MLH1 status and cell-death response in
the absence of functional p53, XIAP was specifically inhibited
using a siRNA strategy in the panel of MLH1-proficient and -
defective EOC cells. The XIAP protein abundance was decreased in
the four cell lines tested 48h after XIAP siRNA transfection
compared with that in siRNA controls (Figure 6A). Data in
Figure 6B show that XIAP protein downregulation in the hMLH1-
defective and p53-mutant A2780MNU1 vector and SKOV3 cells
had no effect on cell viability as measured by the Trypan blue
exclusion assay. This result is consistent with an earlier report
(Sasaki et al, 2000) suggesting that functional p53 is necessary for cells
to respond to XIAP inhibition. In contrast, specific XIAP down-
regulation in p53-defective, MLH1-proficient cells (A2780MNU1-
MLH1 and OVCAR3) caused significant reductions in cell viability;
survival of EOC cells was reduced by B75% compared with that of
untreated cells or of cells treated with control siRNA.
Apoptotic cell populations were quantified using antibodies to
active caspase-3-PE by flow cytometry (Figure 6C), which revealed
a significant increase in the number of cells positive for active
caspase-3 protein in the A2780MNU1-MLH1 cells treated with
XIAP siRNA compared with the A2780MNU1 vector. Furthermore,
the immunoblot analysis (Figure 6D) of protein lysates of XIAP
siRNA-treated MLH1-proficient cells (A2780-MNU1-MLH1 shown
here) showed decreased inactive procaspase-9 levels. The com-
bined treatment of XIAP siRNA with cisplatin did not result in
greatly enhanced (i.e., synergistic) cytotoxic responses relative to
either single exposure under these conditions (data not shown),
indicating a need for testing other XIAP inhibitors and/or dosing
regimens with cisplatin. Alternatively, a potent synergistic or
additive effect of cisplatin and XIAP inhibition expression may
require the presence of both wt-p53 and MLH1. Together, these
data suggest that, similar to cisplatin-induced apoptosis, cell death
mediated by XIAP inhibition in EOC cells with inactive p53 seems
to require the presence of MLH1.
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Figure 3 Analysis of XIAP expression in lysates from 6-TG-treated
ovarian cells: immunoblot analysis of XIAP (55kDa intact and 30kDa
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sDISCUSSION
To understand the influence of MLH1 status on CR and long-term
survival of advanced EOC patients, we have investigated the
apoptotic signalling pathways engaged in p53-deficient ovarian
cancer cells in response to chemotherapeutic agents, cisplatin and
6-TG, and have identified a novel link between the expression of
the mismatch repair protein MLH1 and the stability of XIAP, an
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Figure 4 Immunblots of PKC-d (80kDa) and its cleavage product (40kDa) in 6-TG (A)-treated cell lysates at indicated concentrations and time points
and in cisplatin (B)-treated lysates at 24h at indicated concentrations.
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santi-apoptotic protein and caspase inhibitor. The XIAP inhibition
and proteolysis were selectively observed in MLH1-proficient cells
undergoing MLH1-dependent apoptosis induced in response to
both 6-TG and cisplatin. In addition, proteolysis of MLH1 was
observed in cells undergoing MLH1-dependent apoptosis. The
MLH1 proteolysis corresponded with increased active forms of
caspase-3 and -9 and significantly decreased cell viability. Our
results suggest that overcoming XIAP-mediated inhibition of
apoptosis is an important signalling event in the MLH1-dependent
induction of apoptosis in p53-deficient ovarian cancer cells. This
functional link between MLH1 and XIAP suggests that XIAP status
may influence the effectiveness of MLH1-dependent responses to
chemotherapy and that an inhibition of XIAP, in particular in
MLH1-proficient cancers, may improve the CR of EOC patients to
chemotherapy.
A number of studies in vitro (Aebi et al, 1996; Brown et al, 1997;
Fink et al, 1998b; O’Brien and Brown, 2006) have reported a
correlation between MMR deficiency and platinum resistance.
Indeed, studies link MMR deficiency with reduced CR to platinum-
based chemotherapy (Fink et al, 1998b; Strathdee et al, 2001;
Gifford et al, 2004). In this study, microarray expression data from
54 patients with advanced stage serous EOC, who had received
either cisplatin or carboplatin as part of their primary chemother-
apeutic treatment, revealed a correlation between a high MLH1
expression in the patients’ tumours and increased CR and survival.
This supports the general concept that DNA damage caused by
platinum drugs is recognised by MMR proteins leading to the
induction of apoptosis. In contrast, in cancer cells with MLH1
deficiency, DNA damage is not sensed by repair proteins, resulting
in a reduced apoptotic response and increased cisplatin resistance.
However, not all studies in EOC patients have shown a direct
relationship between MMR deficiency due to decreased MLH1 and
cisplatin resistance (Scartozzi et al, 2003; Helleman et al, 2006).
Interestingly, Scartozzi et al (2003) reported that MLH1 loss in a
small number of stage III–IV EOC patient tumours correlated with
improved survival. The tumour set from this study comprised only
44% serous EOC analysed by immunohistochemistry compared
with our report wherein 100% serous EOCs were analysed by
microarray, possibly attributing the discrepancy to multiple
histological types. A common thread, however, is the potential of
an alternate MMR-independent role of MLH1 in acquired cisplatin
resistance, a mechanism still unclear (O’Brien and Brown, 2006).
A differential response of cells with proficient- and deficient-
MLH1 in sensitivity to cisplatin and 6-TG in ovarian cells was
observed in this study. The presence of wt MLH1 (OVCAR3) or a
re-expression in an MLH1-defective A2780 variant did not
significantly alter the proliferation rate in cisplatin response, but
significantly increased sensitivity to 6-TG, a chemotherapeutic
purine nucleoside analogue, the primary mechanism of action of
which is dependent on the presence of a functional DNA MMR
system (Hawn et al, 1995; Buermeyer et al, 1999; Yan et al, 2003)
consistent with earlier reports (Aquilina et al, 2000; Branch et al,
2000). However, both 6-TG and cisplatin induced an MLH1-
dependent apoptosis and arrest in the G2/M phase of cell cycle
(our unpublished observations), consistent with earlier reports in
OVCAR3 (Aquilina et al, 2000; Kolfschoten et al, 2002) (O’Brien
and Brown, 2006). The MLH1 proteolysis in cells undergoing
apoptosis correlated with the increased expression of active forms
of caspase-3 and -9. Chen et al (2004), using
35S-labelled full-length
MLH1 protein in an in vitro assay, have shown that MLH1 is
cleaved at Asp418 specifically by caspase-3, leading to the partial
translocation of MLH1 from the nucleus to the cytoplasm and the
release of a pro-apoptotic C-terminal fragment, similar to the 44-
kDa MLH1 fragment identified after cisplatin and 6-TG treatment
in this study. These data suggest that ovarian cancer cells
undergoing MLH1-dependent, chemotherapy-induced apoptosis
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Figure 6 Effect of XIAP siRNA in ovarian cancer cells. Cells were treated with indicated siRNA for 48h. (A) Immunoblot analysis of the XIAP protein
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ssignal XIAP destabilisation and release of active caspase-3. In this
response, MLH1 appears functionally similar to other DNA
damage-sensing proteins such as ICAD; cleavage of ICAD by
caspase-3 generates a pro-apoptotic fragment that further in-
creases apoptotic signalling (Tang and Kidd, 1998). Whether the
cleaved MLH1 fragments remain associated as a heterodimer
to increase apoptotic signalling is the subject of ongoing
investigation.
A defect in caspase activation because of the expression of anti-
apoptotic proteins such as XIAP is believed to be an important
mechanism of acquired therapeutic resistance in multiple cancer
models (Sasaki et al, 2000; Li et al, 2001; Mansouri et al, 2003;
Amantana et al, 2004; Yang et al, 2005; Schimmer et al, 2006; Aird
et al, 2008). It has been shown that the inability of cisplatin to
induce apoptosis in EOC may be because of its inability to
suppress XIAP with the corollary that XIAP may be overexpressed
in cisplatin-resistant EOC. The XIAP inhibitors induce apoptosis
by relieving its inhibition on caspases; however, Sasaki et al (2000)
using an adenoviral antisense construct have reported that XIAP
inhibition induced apoptosis only in wt-p53 cells (A2780 cisplatin
sensitive and C13, cisplatin resistant) and not in p53-mutant/null
cells (cisplatin resistant A2780cp or SKOV3). Similarities can be
drawn as the C13 and A2780 cells are MLH1 proficient and the
other two are MLH1 deficient. In addition, in this study, XIAP
inhibition decreased cell viability and corresponded with MLH1
proteolysis only in MLH1 proficient although p53-mutant ovarian
cancer cells and was ineffective in MLH1-deficient cells, revealing a
potential p53-independent but MLH1-dependent effect. However,
no significant synergy was observed using XIAP siRNA in
combination with cisplatin, suggesting the possibility that the
presence of both p53 and MLH1 would be critical for a potent
response. Further studies testing various dosing regimens are
necessary to evaluate whether any potential synergy exists between
cisplatin and XIAP inhibition in MLH1-proficient ovarian cancer
cells. Although, MLH1 proteolysis corresponded with a decrease in
inactive procaspase-9 and an increase in caspase-3 in the cell-death
response to XIAP inhibition, it would be important to determine
whether MLH1 is indeed a direct substrate of caspases in cancer
cells. As targeting XIAP is an attractive anticancer strategy
(Schimmer et al, 2006), MLH1 expression may therefore be useful
for predicting response to XIAP inhibitors alone or in combination
with chemotherapy in EOC patients.
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